|
Home » News and Events » Events » Webcast
Implementing the DRA Medicaid Drug Payment Provisions:
The Final Rule
Recorded Webcast - Presented Wednesday, August 8, 2007
On July 17, 2007, after considering comments from the public, CMS published its
final rule implementing the requirements of the Deficit Reduction Act (DRA), effective
October 1, 2007, including the directive to promulgate regulations on the calculation
of AMP. The final rule varies considerably from the proposed rule in several key
areas and significantly changes the methodology for calculating AMP and Best Price
under the Medicaid Drug Rebate Program.
This presentation will address the CMS's final rule, including information on calculating
monthly and quarterly AMP, reporting CPP, transactions included/excluded from AMP
and best price, bundled sales and authorized generic sales.
Join us to have a greater insight on:
- What calculations must be reported to CMS on monthly and quarterly basis
- What customers are included/excluded from the retail pharmacy class of trade
- How should price reporting systems treat lagged discounts, service fees, price concessions
to PBMs, and patient coupons
- How must companies report bundled discounts
- What is the impact of the final rule on sales of authorized generics through licensees
- How does the final rule affect the 340B program
- How base date AMP can be restated
Who Should Attend:
If you are involved in pharmaceutical or biotech commercial contracting, managed
markets, finance, information management, government compliance, and contract operations
disciplines, this is a program you can't afford to miss!
Register now: Please provide the following information (all fields are required).
|
|
